Abstract:Importance Emerging meta-analytical evidence indicates that baseline exposure to antipsychotics is associated with an increased risk of transitioning to psychosis in individuals at clinical high-risk for psychosis (CHR-P) and that such effect is not a result of pretest risk enrichment. However, to maximize its translational utility for prognostic stratification in clinical practice, testing for the potential presence of a dose-response association is crucial. Objective To test whether the negative prognostic effect of baseline antipsychotic exposure in individuals at CHR-P follows a dose-effect pattern, as indicated by mean chlorpromazine equivalent doses (CPZ-ED). Data Sources MEDLINE and Cochrane Library, performed up to August 31, 2023, searching for English-language studies on individuals at CHR-P reporting data on exposure to antipsychotics at baseline and detailed information on dosage by transition status. Study Selection Studies that provided information on antipsychotic exposure at baseline and included detailed dosage data categorized by transition status. Data Extraction and Synthesis Eligible studies were identified following PRISMA guidelines and evaluated independently by 2 reviewers with the Newcastle-Ottawa Scale for assessing the quality of nonrandomized studies in meta-analyses. Main Outcomes and Measures The primary outcome was transition to psychosis in individuals at CHR-P who were receiving antipsychotic treatment at baseline, measured by baseline mean CPZ-ED in individuals at CHR-P who transitioned to psychosis compared to those who did not. Results Eight studies were included in the systematic review and meta-analysis. Among 290 individuals at CHR-P (mean [SD] age, 19.4 [2.6] years) who were exposed to antipsychotics at baseline and remained in contact up to the completion of the study, 66 converted to psychosis and 224 did not. The mean CPZ-ED ranged 60 to 395 mg/d in those who converted and 13 to 224 mg/d in those who did not. Those who converted to psychosis had higher CPZ-ED than those who did not in both the common-effects model (Hedges g , 0.41; 95% CI, 0.12-0.70; z , 2.78; P = .005) and in the random-effects model (Hedges g , 0.41; 95% CI, 0.15-0.67; z , 3.69; P = .008; τ 2 , 0.0). There was no relevant heterogeneity (Cochran Q , 3.99; df , 7; P = .78; I 2 , 0.0%; 95% CI, 0.0-68.0). The radial plot indicated a good fit of the model. Conclusions and Relevance In individuals at CHR-P who were exposed to antipsychotics at baseline, those receiving higher antipsychotic doses demonstrated an increased likelihood of transitioning to psychosis. This meta-analytic evidence of putative dose-effect association confirms that baseline antipsychotic exposure and the corresponding dosage carry salient prognostic information that could improve current CHR-P criteria-based risk stratification at inception.

Further Evidence That Antipsychotic Medication Does Not Prevent Long-Term Psychosis in Higher-Risk Individuals

Real-world Effectiveness of Antipsychotic Treatment in Psychosis Prevention in a 3-Year Cohort of 517 Individuals at Clinical High Risk from the SHARP (shanghai at Risk for Psychosis).

Antipsychotic Exposure in Clinical High Risk of Psychosis

Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study

Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period

Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (shanghai at Risk for Psychosis-Phase 2)

Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice

Individualized Risk Components Guiding Antipsychotic Delivery in Patients with a Clinical High Risk of Psychosis: Application of a Risk Calculator

Antipsychotic Prescription, Assumption and Conversion to Psychosis: Resolving Missing Clinical Links to Optimize Prevention Through Precision

Subtypes of Clinical High Risk for Psychosis That Predict Antipsychotic Effectiveness in Long-Term Remission

Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk

Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis

When to Initiate Antipsychotic Treatment for Psychotic Symptoms: at the Premorbid Phase or First Episode of Psychosis?

Clinical High-Risk for Psychosis (CHR-P) circa 2024: Synoptic analysis and synthesis of contemporary treatment guidelines

Analysis of related factors of clinical outcome in patients with clinical high risk syndromes

A Comparison of Conversion Rates, Clinical Profiles and Predictors of Outcomes in Two Independent Samples of Individuals at Clinical High Risk for Psychosis in China

Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High Risk for Psychosis

Poor functional recovery is better predicted than conversion in studies of outcomes of clinical high risk of psychosis: insight from SHARP

Non-psychotic Outcomes in Young People at Ultra-High Risk of Developing a Psychotic Disorder: A Long-Term Follow-up Study

Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High-Risk for Psychosis

Adverse outcome analysis in people at clinical high risk for psychosis: results from a 2-year Italian follow-up study